Exposed: 10 CENT Crypto to Explode April 20th?

The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…

Robert E. Mcnamara net worth and biography

Robert Mcnamara Biography and Net Worth

Director of Axonics

Robert McNamara has served as Axonics' Audit Committee Chairman since November 2018. He is an accomplished senior executive with demonstrated success in public and privately held companies with global operations in highly competitive industries, including medical device, software and high technology. He has extensive experience in initial public offerings (IPOs), mergers and acquisitions (M&A), operations and financial management at early stage, high growth and mature companies. Mr. McNamara has raised significant capital (more than $500M) in public offerings and private placements, while managing investor relations, international operations and strategic planning. As CFO, he has managed and led three IPOs, six acquisitions/mergers, including two exceeding $1B each, and numerous rounds of venture capital funding. In 2015, he was named Acquisition International Magazine’s Texas Healthcare CFO of the Year. He has been the EVP/CFO of four public medical device companies. He is currently a member of the Board of Directors for Xtant Medical, chairs its Compensation Committee and is a member of its Audit Committee. In addition, he was elected council member and served as mayor of Menlo Park, CA.

Mr. McNamara is a CPA (nonpracticing). He has a B.S. from University of San Francisco and an M.B.A. from University of Pennsylvania’s Wharton School.

What is Robert E. Mcnamara's net worth?: The estimated net worth of Robert E. Mcnamara is at least $499,050.00 as of January 13th, 2021. Mr. Mcnamara owns 7,500 shares of Axonics stock worth more than $499,050 as of April 26th. This net worth approximation does not reflect any other assets that Mr. Mcnamara may own. Learn More about Robert E. Mcnamara's net worth.
How do I contact Robert E. Mcnamara?: The corporate mailing address for Mr. Mcnamara and other Axonics executives is 26 TECHNOLOGY DRIVE, IRVINE CA, 92618. Axonics can also be reached via phone at (949) 396-6322 and via email at [email protected]. Learn More on Robert E. Mcnamara's contact information.
Has Robert E. Mcnamara been buying or selling shares of Axonics?: Robert E. Mcnamara has not been actively trading shares of Axonics in the last ninety days. Most recently, Robert E. Mcnamara sold 9,167 shares of the business's stock in a transaction on Wednesday, January 13th. The shares were sold at an average price of $51.83, for a transaction totalling $475,125.61. Following the completion of the sale, the director now directly owns 7,500 shares of the company's stock, valued at $388,725. Learn More on Robert E. Mcnamara's trading history.
Who are Axonics' active insiders?: Axonics' insider roster includes Juliet Bakker (Director), Raymond Cohen (CEO), Danny Dearen (Insider), Alfred Ford, Jr. (Insider), Kari Keese (CFO), Jane Kiernan (Director), Esteban Lopez (Director), Robert Mcnamara (Director), Karen Noblett (Insider), Rinda Sama (COO), and John Woock (CMO). Learn More on Axonics' active insiders.
Are insiders buying or selling shares of Axonics?: During the last year, insiders at the sold shares 11 times. They sold a total of 121,779 shares worth more than $7,915,525.91. The most recent insider tranaction occured on January, 31st when insider Karen Noblett sold 11,288 shares worth more than $764,649.12. Insiders at Axonics own 1.9% of the company. Learn More about insider trades at Axonics.
Information on this page was last updated on 1/31/2024.

Robert E. Mcnamara Insider Trading History at Axonics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/13/2021	Sell	9,167	$51.83	$475,125.61	7,500

Robert E. Mcnamara Buying and Selling Activity at Axonics

Axonics Company Overview

Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

Today's Range

Now: $66.54

$66.47

$66.75

50 Day Range

MA: $67.95

$66.47

$69.65

2 Week Range

Now: $66.54

$47.59

$69.68

Volume

484,280 shs

Average Volume

1,261,526 shs

Market Capitalization

$3.39 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.56

Exposed: 10 CENT Crypto to Explode April 20th?

From True Market Insiders | Ad